Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes
Description
CONCLUSION: The present study supports that rituximab is an effective and well tolerated treatment for refractory anti-AChR + and DSN MG patients, while anti-MuSK + remains the group experiencing the greater benefits.
